GURUFOCUS.COM » STOCK LIST » USA » NYSE » Bristol-Myers Squibb Co (NYSE:BMY) » Definitions » EV-to-EBIT
Switch to:

Bristol-Myers Squibb Co EV-to-EBIT

: 21.09 (As of Today)
View and export this data going back to 1952. Start your Free Trial

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Bristol-Myers Squibb Co's Enterprise Value is $188,767 Mil. Bristol-Myers Squibb Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2022 was $8,950 Mil. Therefore, Bristol-Myers Squibb Co's EV-to-EBIT for today is 21.09.

The historical rank and industry rank for Bristol-Myers Squibb Co's EV-to-EBIT or its related term are showing as below:

BMY' s EV-to-EBIT Range Over the Past 10 Years
Min: -70.86   Med: 21   Max: 126.73
Current: 21.35

During the past 13 years, the highest EV-to-EBIT of Bristol-Myers Squibb Co was 126.73. The lowest was -70.86. And the median was 21.00.

BMY's EV-to-EBIT is ranked worse than
62.33% of 669 companies
in the Drug Manufacturers industry
Industry Median: 15.93 vs BMY: 21.35

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Bristol-Myers Squibb Co's Enterprise Value for the quarter that ended in Jun. 2022 was $194,232 Mil. Bristol-Myers Squibb Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2022 was $8,950 Mil. Bristol-Myers Squibb Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2022 was 4.61%.


Bristol-Myers Squibb Co EV-to-EBIT Historical Data

The historical data trend for Bristol-Myers Squibb Co's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bristol-Myers Squibb Co Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
EV-to-EBIT
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.93 13.51 31.12 -31.75 17.25

Bristol-Myers Squibb Co Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
EV-to-EBIT Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -66.31 -56.74 17.25 21.76 21.70

Competitive Comparison

For the Drug Manufacturers - General subindustry, Bristol-Myers Squibb Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Bristol-Myers Squibb Co EV-to-EBIT Distribution

For the Drug Manufacturers industry and Healthcare sector, Bristol-Myers Squibb Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Bristol-Myers Squibb Co's EV-to-EBIT falls into.



Bristol-Myers Squibb Co EV-to-EBIT Calculation

Bristol-Myers Squibb Co's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=188767.099/8950
=21.09

Bristol-Myers Squibb Co's current Enterprise Value is $188,767 Mil.
Bristol-Myers Squibb Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $8,950 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bristol-Myers Squibb Co  (NYSE:BMY) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Bristol-Myers Squibb Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2022 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Jun. 2022 ) =EBIT / Enterprise Value (Q: Jun. 2022 )
=8950/194232
=4.61 %

Bristol-Myers Squibb Co's Enterprise Value for the quarter that ended in Jun. 2022 was $194,232 Mil.
Bristol-Myers Squibb Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $8,950 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bristol-Myers Squibb Co EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Bristol-Myers Squibb Co's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Bristol-Myers Squibb Co Business Description

Bristol-Myers Squibb Co logo
Address
430 East 29th Street, 14th Floor, New York, NY, USA, 10016
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, oncology, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Executives
Greenlees Sharon officer: SVP & Controller BRISTOL MYERS SQUIBB ROUTE 206 & PROVINCE LINE ROAD PRINCETON NJ 08543
Shanahan Karin officer: EVP, Glob. Prod. Dev. & Supply BRISTOL MYERS SQUIBB ROUTE 206 & PROVINCE LINE ROAD PRINCETON NJ 08543
Meyers Gregory Scott officer: EVP, Chief Digital & Tech Off. BRISTOL MYERS SQUIBB ROUTE 206 & PROVINCE LINE ROAD PRINCETON NJ 08543
Weese Michelle officer: EVP, Corporate Affairs BRISTOL MYERS SQUIBB ROUTE 206 & PROVINCE LINE ROAD PRINCETON NJ 08543
Hidalgo Medina Manuel director BRISTOL MYERS SQUIBB 430 E. 29TH STREET, 14TH FLOOR NEW YORK NY 10016
Rice Derica W director 1000 NICOLLET MALL TPS-3155 MINNEAPOLIS MN 55403
Price Paula A director ONE CVS DRIVE WOONSOCKET RI 02895
Mily Elizabeth officer: EVP, Strategy & BD BRISTOL-MYERS SQUIBB COMPANY ROUTE 206 & PROVENCE LINE ROAD PRINCETON NJ 08540
Metcalfe Kathryn officer: EVP, Corporate Affairs BRISTOL-MYERS SQUIBB COMPANY ROUTE 206 & PROVINCE LINE ROAD PRINCETON NJ 08543
Vessey Rupert officer: Pres., Research & Early Dev. C/O CELGENE CORPORATION 86 MORRIS AVENUE SUMMIT NJ 07901
Elkins David V officer: EVP, Chief Financial Officer C/O BECTON, DICKINSON AND COMPANY 1 BECTON DRIVE FRANKLIN LAKES NJ 07417
Bonney Michael W director 65 HAYDEN AVE LEXINGTON MA 02421
Yale Phyllis R director
Ahmed Nadim officer: President, Hematology C/O CELGENE CORPORATION 86 MORRIS AVENUE SUMMIT NJ 07901
Haller Julia A director C/O CELGENE CORPORATION 86 MORRIS AVENUE SUMMIT NJ 07901

Bristol-Myers Squibb Co Headlines

From GuruFocus

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)